Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Calcimedica Inc. is currently prosecuting 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, which introduces a variety of review styles into the company's patent strategy. The workload is also spread across 2 distinct art units, reflecting a range of technical classifications for the pending subject matter. This distribution indicates that the company is navigating multiple examination processes simultaneously within the biotechnology sector.
The busiest examiner for Calcimedica Inc. is WHITE, DAWANNA SHAR-DAY, who is assigned 1 busiest examiner pending office action. This 1 busiest examiner pending office action represents one of the 2 pending office actions currently active for the portfolio. With 2 distinct examiners and 2 distinct art units involved, the company's prosecution outcomes are not concentrated under a single official. Practitioners must manage 2 distinct timelines and respond to the specific requirements of 2 different examiners. This structure provides a level of diversification in the company's pursuit of patent protection for its 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18056973 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | RZECZYCKI, PHILLIP MATTHEW | 15d |
| 18454292 | CRAC CHANNEL INHIBITOR COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18454292 | CRAC CHANNEL INHIBITOR COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | 1627 | §103DP | Final Rejection | — | Pending | Aug 23, 2023 |
| 18056973 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103 | Non-Final OA | 15d | Pending | Nov 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial